Biotechnology Assets Sa · BME:BST
Biotechnology Assets Sa — ADL Bionatur Solutions — Investor Presentation (May 2019)
18 slides from Biotechnology Assets Sa's investor presentation, May 14, 2019
Slide 1: Company Presentation
Company Presentation May 2019
Slide 2: Disclaimer
Disclaimer This presentation may contain forward-looking, work-in-progress statements based on current assumptions and forecasts made by ADL Bionatur Solutions, S.A. (“ADL” or the “Company”) or the Company’s management. Various known and unknown risks, uncertainties and other factors could lead to m
Slide 3: Executive Summary
Executive Summary Market Leading Fermentation Company focused on the Health, Beauty and Wellness Industries 1 Largest fermentation production plant in Southern Europe (based in Léon, Spain) supported by substantial fermentation expertise 2019 Total Revenues expected to be €50m-€55m up from €25.2m in
Slide 4: ADL Bionatur Solutions: Building a Leading Fermentation Company
ADL Bionatur Solutions: Building a Leading Fermentation Company 2018 Reverse Merger of ADL and Bionaturis has created a market-leading expert in fermentation manufacturing for the the Health, Beauty and Wellness industries Market-leading contract manufacturer offering fermentation of Advanced Interm
Slide 5: Our Journey
Our Journey Revenue Mix between Business Units 89% 2019 CMO/API €50-55m Sales 2019E Target underpinned by 2018 multiple long term contracts with international leading 11% Reverse Merger with companies Bionaturis. Listed on the CRO/proprietary Alternative Equity technologies and molecules 2017 Market
Slide 6: ADL Bionatur Snapshot
ADL Bionatur Snapshot Over 330 employees worldwide Research facilities in Barcelona, Jerez and San About 30% in R&D Sebastian, Spain R&D services with scale-up and regulatory affairs experience 2,400m3 Fermentation Production Capacity, León Powerful proprietary portfolio of 10 patent FDA (US), AEMPS
Slide 7: ADL Bionatur Snapshot (Continued)
ADL Bionatur Snapshot (Continued) Total Revenue (€m) (Bionatur included from ’18 onwards) Blue-Chip Customer Base (Selected Partners) CAGR 15-19: >90% 50- 55 25.2 12.8 4,7 6,1 0,0 FY14 FY15 FY16 FY17 FY18 FY19E Overview of Business Units and Geographic Presence SPAIN USA Léon, Spain Jerez, Spain Bar
Slide 8: We Are A Leading Fermentation Player
We Are A Leading Fermentation Player Who we are What we do ADL BioPharma is the main business unit We offer our customers: of the Group and is primarily focused on Significant industrial capacity and CMO/CDMO for leading partners know-how for the manufacture of any We are a biopharma company product
Slide 9: State-of-the-Art Facilities with Capacity to Support Future Growth
State-of-the-Art Facilities with Capacity to Support Future Growth Development and production of CMO Manufacturing of APIs • Biological laboratories: 2-5l fermenters, • Fermentation Pilot Plant: Renovation Sterile Plant: High Potency Building: incubation chambers, master cell bank, and start-up of a
Slide 10: Over the Medium Term ADL Revenue Will Be Driven By CMO/API
Over the Medium Term ADL Revenue Will Be Driven By CMO/API CMO API Fermentation Sterile SSP Long-term contracts with loyal customers to manufacture Manufacturing and commercialization of active pharmaceutical high-value biologically active materials for third parties for ingredients (“APIs”) bas
Slide 11: We Will Drive Future Growth Through Our Own Targeted Process R&D
We Will Drive Future Growth Through Our Own Targeted Process R&D Based on our proprietary R & D programs, we are developing products that can be derived via fermentation, manufactured in our facilities and then licensed to commercial partners for marketing We target known and approved off-patent hig
Slide 12: The Group Also Offers Niche R&D Services to Industry
The Group Also Offers Niche R&D Services to Industry Following the merger with Bioanturis, the Group includes B2B businesses such as Industrial Tailwinds Provide Attractive Outlook Biobide and ZIP which work with multinational laboratories and national champions from pharma, biotech, chemistry, cosm
Slide 13: Key Events 2018
Key Events 2018 Reverse acquisition of ADL Biopharma and Bionaturis completed Listing on the Spanish Mercado Alternativo Bursátil (MAB, Ticker: ADL) Long-term manufacturing contracts signed with US- and EU-based partners: Jan 2018: Started 6-year contract with major client with total revenue of €142
Slide 14: Highlights of 2018 Financial Performance
Highlights of 2018 Financial Performance Substantial EBITDA Cash €3m at the 1 revenue growth 2 significantly 3 end of December continued improved 2018 New international Improved Improved margins customers utilization In-house Continuous production of Successful capital improvement of Bionaturis incr
Slide 15: We Will Continue to Pursue Profitable Growth
We Will Continue to Pursue Profitable Growth ~50% organic revenue growth through forecast period Full capacity committed by end 2019 30% EBITDA margin target • c. €50m-€55m in expected revenue in 2019 up from • Significant increase in • 2019 expected to show strong profitability €25.2m in 2018 capac
Slide 16: Led by an Experienced Management Team
Led by an Experienced Management Team Pilar de la Huerta Juan Andrés Corrochano GROUP CEO CFO CEO OF THE INDUSTRIAL DIV MSC Economics Degree in Business and Law Over 20 years experience managing Over 15 years of experience in public and private companies in the corporate, financial and integral phar
Slide 17: Share Price and Capital Structure Overview
Share Price and Capital Structure Overview Basic Information Shareholder Structure** Ticker “ADL.MS” Victor Infante 5,1% Shares outstanding: 39,389,067 Black Toro Capital Current market cap*: >€90m 73,2% Net debt at 31 Dec 2018: €42.9m Free Float 21.7% Analyst Coverage Broker Target Price Ba
Slide 18: Contact
Contact ADL Bionatur Solutions Pilar de la Huerta, CEO Av. del Desarrollo Tecnológico, 11 11591 Jerez de la Frontera, Cádiz Tel.: +34 987895801 Email: ir@adlbionatur.com www.adlbionatur.com
ADL Bionatur Solutions — Investor Presentation (May 2019) on 6ix